Design and Characterization of a Metalloproteinase Inhibitor-Tethered Resin for the Detection of Active MMPs in Biological Samples

Chemistry and Biology

Volumn 13, Issue 4, 2006, Pages 379-386

  Hesek, Dusan ^a   Toth, Marta ^a,b   Meroueh, Samy O ^a   Brown, Stephen ^a   Zhao, Huiren ^b   Sakr, Wael ^b   Fridman, Rafael ^b   Mobashery, Shahriar ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CELLCYCLE; CHEMBIO

Indexed keywords

GELATINASE; MATRIX METALLOPROTEINASE; PROTEINASE INHIBITOR; RECOMBINANT PROTEIN; RESIN;

ARTICLE; BREAST TUMOR; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; ENZYMOLOGY; FEMALE; HUMAN; IN VITRO STUDY; LARYNX TUMOR; SYNTHESIS;

BREAST NEOPLASMS; DRUG DESIGN; FEMALE; GELATINASES; HUMANS; LARYNGEAL NEOPLASMS; MATRIX METALLOPROTEINASES; MATRIX METALLOPROTEINASES, MEMBRANE-ASSOCIATED; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; RESINS, SYNTHETIC;

EID: 33646061062     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2006.01.012     Document Type: Article

References (58)

1. Sporn M.B. The war on cancer. Lancet 347 (1996) 1377-1381
2. McCawley L.J., and Matrisian L.M. Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol. Med. Today 6 (2000) 149-156
3. Stetler-Stevenson W.G. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J. Clin. Invest. 103 (1999) 1237-1241
4. Stetler-Stevenson W.G., and Yu A.E. Proteases in invasion: matrix metalloproteinases. Semin. Cancer Biol. 11 (2001) 143-152
5. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin. Cancer Biol. 10 (2000) 415-433
6. Brown P.D., Bloxidge R.E., Anderson E., and Howell A. Expression of activated gelatinase in human invasive breast carcinoma. Clin. Exp. Metastasis 11 (1993) 183-189
7. Bartsch J.E., Staren E.D., and Appert H.E. Matrix metalloproteinase expression in breast cancer. J. Surg. Res. 110 (2003) 383-392
8. Shiomi T., and Okada Y. MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Cancer Metastasis Rev. 22 (2003) 145-152
9. Nakopoulou L., Tsirmpa I., Alexandrou P., Louvrou A., Ampela C., Markaki S., and Davaris P.S. MMP-2 protein in invasive breast cancer and the impact of MMP-2/TIMP-2 phenotype on overall survival. Breast Cancer Res. Treat. 77 (2003) 145-155
10. Brown P.D. Clinical studies with matrix metalloproteinase inhibitors. APMIS 107 (1999) 174-180
11. Hidalgo M., and Eckhardt S.G. Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl. Cancer Inst. 93 (2001) 178-193
12. Zucker S., Cao J., and Chen W.T. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19 (2000) 6642-6650
13. Price A., Shi Q., Morris D., Wilcox M.E., Brasher P.M., Rewcastle N.B., Shalinsky D., Zou H., Appelt K., Johnston R.N., et al. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin. Cancer Res. 5 (1999) 845-854
14. Steward W.P. Marimastat (BB2516): current status of development. Cancer Chemother. Pharmacol. 43 Suppl. (1999) S56-S60
15. Michaelides M.R., and Curtin M.L. Recent advances in matrix metalloproteinase inhibitors research. Curr. Pharm. Des. 5 (1999) 787-819
16. Coussens L.M., Fingleton B., and Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295 (2002) 2387-2392
17. Kruger A., Arlt M.J., Gerg M., Kopitz C., Bernardo M.M., Chang M., Mobashery S., and Fridman R. Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. Cancer Res. 65 (2005) 3523-3526
18. Nemeth J.A., Yousif R., Herzog M., Che M., Upadhyay J., Shekarriz B., Bhagat S., Mullins C., Fridman R., and Cher M.L. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J. Natl. Cancer Inst. 94 (2002) 17-25
19. Folgueras A.R., Pendas A.M., Sanchez L.M., and Lopez-Otin C. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int. J. Dev. Biol. 48 (2004) 411-424
20. Deryugina E.I., Zijlstra A., Partridge J.J., Kupriyanova T.A., Madsen M.A., Papagiannakopoulos T., and Quigley J.P. Unexpected effect of matrix metalloproteinase down-regulation on vascular intravasation and metastasis of human fibrosarcoma cells selected in vivo for high rates of dissemination. Cancer Res. 65 (2005) 10959-10969
21. Fingleton B. Matrix metalloproteinases: roles in cancer and metastasis. Front. Biosci. 11 (2006) 479-491
22. Bergers G., Javaherian K., Lo K.M., Folkman J., and Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284 (1999) 808-812
23. Eccles S.A., Box G.M., Court W.J., Bone E.A., Thomas W., and Brown P.D. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res. 56 (1996) 2815-2822
24. Egeblad M., and Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2 (2002) 161-174
25. Overall C.M. Molecular determinants of metalloproteinase substrate specificity: matrix metalloproteinase substrate binding domains, modules, and exosites. Mol. Biotechnol. 22 (2002) 51-86
26. Matrisian L.M., Sledge Jr. G.W., and Mohla S. Extracellular proteolysis and cancer: meeting summary and future directions. Cancer Res. 63 (2003) 6105-6109
27. Murphy G., Stanton H., Cowell S., Butler G., Knauper V., Atkinson S., and Gavrilovic J. Mechanisms for pro matrix metalloproteinase activation. APMIS 107 (1999) 38-44
28. Murphy G., Knauper V., Cowell S., Hembry R., Stanton H., Butler G., Freije J., Pendas A.M., and Lopez-Otin C. Evaluation of some newer matrix metalloproteinases. Ann. N Y Acad. Sci. 878 (1999) 25-39
29. Morgunova E., Tuuttila A., Bergmann U., Isupov M., Lindqvist Y., Schneider G., and Tryggvason K. Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. Science 284 (1999) 1667-1670
30. Kotra L.P., Cross J.B., Shimura Y., Fridman R., Schlegel H.B., and Mobashery S. Insight into the complex and dynamic process of activation of matrix metalloproteinases. J. Am. Chem. Soc. 123 (2001) 3108-3113
31. Brew K., Dinakarpandian D., and Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta 1477 (2000) 267-283
32. Nagase H., and Woessner Jr. J.F. Matrix metalloproteinases. J. Biol. Chem. 274 (1999) 21491-21494
33. Grams F., Crimmin M., Hinnes L., Huxley P., Pieper M., Tschesche H., and Bode W. Structure determination and analysis of human neutrophil collagenase complexed with a hydroxamate inhibitor. Biochemistry 34 (1995) 14012-14020
34. Lang R., Kocourek A., Braun M., Tschesche H., Huber R., Bode W., and Maskos K. Substrate specificity determinants of human macrophage elastase (MMP-12) based on the 1.1 A crystal structure. J. Mol. Biol. 312 (2001) 731-742
35. Gervasi D.C., Raz A., Dehem M., Yang M., Kurkinen M., and Fridman R. Carbohydrate-mediated regulation of matrix metalloproteinase-2 activation in normal human fibroblasts and fibrosarcoma cells. Biochem. Biophys. Res. Commun. 228 (1996) 530-538
36. Strongin A.Y., Collier I., Bannikov G., Marmer B.L., Grant G.A., and Goldberg G.I. Mechanism of cell surface activation of 72-kDa type IV collagenase: isolation of the activated form of the membrane metalloprotease. J. Biol. Chem. 270 (1995) 5331-5338
37. Hernandez-Barrantes S., Toth M., Bernardo M.M., Yurkova M., Gervasi D.C., Raz Y., Sang Q.A., and Fridman R. Binding of active (57 kDa) membrane type 1-matrix metalloproteinase (MT1-MMP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and pro-MMP-2 activation. J. Biol. Chem. 275 (2000) 12080-12089
38. Freije J.R., and Bischoff R. Activity-based enrichment of matrix metalloproteinases using reversible inhibitors as affinity ligands. J. Chromatogr. A. 1009 (2003) 155-169
39. Moore W.M., and Spilburg C.A. Purification of human collagenases with a hydroxamic acid affinity column. Biochemistry 25 (1986) 5189-5195
40. Reyda S., Jacob E., Zwilling R., and Stocker W. cDNA cloning, bacterial expression, in vitro renaturation and affinity purification of the zinc endopeptidase astacin. Biochem. J. 344 (1999) 851-857
41. Hardern I.M., Knauper V., Ernill R.J., Taylor I.W., Cooper K.L., and Abbott W.M. An analysis of two refolding routes for a C-terminally truncated human collagenase-3 expressed in Escherichia coli. Protein Expr. Purif. 19 (2000) 246-252
42. Jenssen K., Sewald K., and Sewald N. Synthesis of marimastat and a marimastat conjugate for affinity chromatography and surface plasmon resonance studies. Bioconjug. Chem. 15 (2004) 594-600
43. Toth M., Osenkowski P., Hesek D., Brown S., Meroueh S., Sakr W., Mobashery S., and Fridman R. Cleavage at the stem region releases an active ectodomain of the membrane type 1 matrix metalloproteinase. Biochem. J. 387 (2005) 497-506
44. Seiki M. Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett. 194 (2003) 1-11
45. Sabeh F., Ota I., Holmbeck K., Birkedal-Hansen H., Soloway P., Balbin M., Lopez-Otin C., Shapiro S., Inada M., Krane S., et al. Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J. Cell Biol. 167 (2004) 769-781
46. Chun T.H., Sabeh F., Ota I., Murphy H., McDonagh K.T., Holmbeck K., Birkedal-Hansen H., Allen E.D., and Weiss S.J. MT1-MMP-dependent neovessel formation within the confines of the three-dimensional extracellular matrix. J. Cell Biol. 167 (2004) 757-767
47. Sternlicht M.D., and Werb Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 17 (2001) 463-516
48. Jessani N., and Cravatt B.F. The development and application of methods for activity-based protein profiling. Curr. Opin. Chem. Biol. 8 (2004) 54-59
49. Baruch A., Jeffery D.A., and Bogyo M. Enzyme activity-it's all about image. Trends Cell Biol. 14 (2004) 29-35
50. Jessani N., Humphrey M., McDonald W.H., Niessen S., Masuda K., Gangadharan B., Yates III J.R., Mueller B.M., and Cravatt B.F. Carcinoma and stromal enzyme activity profiles associated with breast tumor growth in vivo. Proc. Natl. Acad. Sci. USA 101 (2004) 13756-13761
51. Saghatelian A., Jessani N., Joseph A., Humphrey M., and Cravatt B.F. Activity-based probes for the proteomic profiling of metalloproteases. Proc. Natl. Acad. Sci. USA 101 (2004) 10000-10005
52. Olson M.W., Gervasi D.C., Mobashery S., and Fridman R. Kinetic analysis of the binding of human matrix metalloproteinase-2 and -9 to tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2. J. Biol. Chem. 272 (1997) 29975-29983
53. Bernardo M.M., and Fridman R. TIMP-2 (tissue inhibitor of metalloproteinase-2) regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after pro-MMP-2 activation by MT1 (membrane type 1)-MMP. Biochem. J. 374 (2003) 739-745
54. Toth M., Chvyrkova I., Bernardo M.M., Hernandez-Barrantes S., and Fridman R. Pro-MMP-9 activation by the MT1-MMP/MMP-2 axis and MMP-3: role of TIMP-2 and plasma membranes. Biochem. Biophys. Res. Commun. 308 (2003) 386-395
55. Galvez B.G., Matias-Roman S., Albar J.P., Sanchez-Madrid F., and Arroyo A.G. Membrane type 1-matrix metalloproteinase is activated during migration of human endothelial cells and modulates endothelial motility and matrix remodeling. J. Biol. Chem. 276 (2001) 37491-37500
56. Fridman R., Toth M., Pena D., and Mobashery S. Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res. 55 (1995) 2548-2555
57. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
58. Toth M., and Fridman R. Assessment of gelatinases (MMP-2 and MMP-9) by gelatin zymography. In: Brooks S.A., and Schumacher U. (Eds). Metastasis Research Protocols: Analysis of Cells and Tissues, Volume 1 (2001), Humana Press, Totowa, NJ 163-174